The Study
Multicenter validation of plasma p‐tau217/ amyloid beta 1‐42 ratio in symptomatic Alzheimer's disease
This study checked if a simple blood test can tell if someone has a brain protein linked to Alzheimer’s, by comparing it to more expensive brain scans and spinal fluid tests. It found the blood test matches those tests really well — but it doesn’t prove the blood test causes Alzheimer’s or can predict who will get it later.
Analysis score
Maximum 44 for a cross-sectional study.
Where the score came from
Scientists tested a blood test that measures two proteins linked to Alzheimer's to see if it can spot brain plaques without needing a spinal tap or brain scan.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 544 / 100
Quality score
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1This means most people could avoid invasive or expensive brain scans — the blood test could tell doctors whether to proceed with further testing or not.
- 2The blood test was right 97.6% of the time when plaques were present, and wrong only 9.2% of the time when they weren't.
- 3It gave unclear results in about 1 in 5 people.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Alzheimer's & Dementia
Year
2026
Authors
A. Moghekar, J. Rock, Richard C Mohs, O. Hansson, E. Stomrud, S. Palmqvist, N. Mattsson‐Carlgren, Sterling C. Johnson, H. Zetterberg, R. R. Radwan, Jessica Junfola, M. Miller, Luna Buitrago, Francesca I De Simone, K. Martin, D. Dickson, Natalya Benina, Douglas M. Hawkins
Related Content
Claims (5)
A specific blood test using the Lumipulse G pTau217/β-Amyloid 1-42 ratio with defined thresholds reduces ambiguous results to 19.6% in adults with cognitive complaints and removes the need for spinal fluid or brain imaging tests in 75.8% of cases.
Blood levels of p-tau217 can identify the presence of amyloid-beta plaques in the brain with 95% to 97% accuracy, allowing Alzheimer's pathology to be detected decades before symptoms appear.
The ratio of pTau217 to β-Amyloid 1-42 in blood provides a more reliable diagnostic test for neurodegenerative conditions than pTau217 alone, with higher accuracy and fewer unclear results.
The blood test that measures the ratio of pTau217 to β-Amyloid 1-42 accurately identifies amyloid buildup in the brain whether the diagnosis is confirmed by spinal fluid analysis or brain imaging.
A blood test called Lumipulse G pTau217/β-Amyloid 1-42 ratio detects amyloid pathology in adults aged 50 and older with cognitive complaints with 97.6% accuracy for identifying true cases and 90.8% accuracy for ruling out false cases, compared to cerebrospinal fluid tests or amyloid PET scans.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.